Research programme: antileukotriene monoclonal antibodies - Lpath

Drug Profile

Research programme: antileukotriene monoclonal antibodies - Lpath

Alternative Names: Altepan™; Anti-leukotriene antibody - Lpath; Leukotriene inhibitors - Lpath

Latest Information Update: 03 Nov 2015

Price : $50

At a glance

  • Originator Lpath
  • Class Monoclonal antibodies
  • Mechanism of Action Leukotriene inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Asthma; Inflammatory bowel diseases

Highest Development Phases

  • Preclinical Asthma; Inflammation; Inflammatory bowel diseases; Respiratory tract disorders

Most Recent Events

  • 28 Jul 2015 Preclinical trials in Inflammatory bowel disease in USA (Parenteral) prior to July 2015
  • 23 Jul 2015 Research programme: antileukotriene monoclonal antibodies - Lpath is available for licensing as of 28 Jul 2015. http://www.lpath.com/
  • 25 Sep 2014 Preclinical trials in Inflammation in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top